L3VLUP
ProSign in

ABT · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ABTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ABT
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterABTLLY
Q3 202027 holders, $24.7bn33 holders, $14.1bn
Q4 202029 holders, $24.8bn29 holders, $17.3bn
Q1 202131 holders, $27.6bn24 holders, $23.0bn
Q2 202129 holders, $26.5bn24 holders, $27.8bn
Q3 202134 holders, $25.4bn31 holders, $29.9bn
Q4 202128 holders, $29.2bn31 holders, $34.7bn
Q1 202234 holders, $24.2bn24 holders, $35.3bn
Q2 202233 holders, $21.5bn33 holders, $42.7bn
Q3 202230 holders, $18.8bn31 holders, $43.4bn
Q4 202225 holders, $20.6bn31 holders, $46.6bn
Q1 202332 holders, $19.2bn33 holders, $44.3bn
Q2 202327 holders, $20.4bn37 holders, $59.6bn
Q3 202330 holders, $17.7bn44 holders, $67.6bn
Q4 202324 holders, $21.0bn45 holders, $73.6bn
Q1 202427 holders, $20.6bn41 holders, $95.3bn
Q2 202437 holders, $16.8bn43 holders, $110bn
Q3 202428 holders, $17.7bn45 holders, $107bn
Q4 202422 holders, $16.6bn46 holders, $93.9bn
Q1 202528 holders, $20.9bn42 holders, $98.4bn
Q2 202526 holders, $21.1bn43 holders, $93.2bn
Q3 202520 holders, $21.3bn39 holders, $86.7bn
Q4 202525 holders, $20.6bn41 holders, $123bn
Q1 202635 holders, $19.1bn39 holders, $106bn
Q2 202636 holders, $15.8bn44 holders, $132bn
ABT

Abbott Laboratories

Holders
36
Reported value
$15.8bn
Buyers
23
Sellers
21

Breadth +2 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Freestone Grove Partners LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, Soros Fund Management LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP, Woodline Partners LP

Only ABT (4)

Element Capital Management LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Southeastern Asset Management Inc

Only LLY (12)

ARK Investment Management LLC, Artisan Partners LP, Brevan Howard Capital Management LP, Capital World Investors, Discovery Capital Management LLC, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Jane Street Group LLC, Schonfeld Strategic Advisors LLC, Susquehanna International Group LLP, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →